Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-O-acyl-muramyldipeptide and synthetic low toxicity analogues of lipid A

Masachika Tsujimoto, Shozo Kotani, Takafumi Okunaga, Takao Kubo, Haruhiko Takada, Takasi Kubo, Tetsuo Shiba, Shoichi Kusumoto, Takashi Takahashi, Yoji Goto, Fumio Kinoshita

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

6-O-Acyl derivatives of N-acetylmuramyl-l-alanyl-d-isoglutamine (MDP) and synthetic, low toxicity lipid-A analogues were examined for their ability to enhance the potency of current viral vaccines. 6-O-(2-Tetradecylhexadecanoyl)-MDP (B30-MDP) in non-irritative vehicles such as physiological saline, phosphate-buffered saline (PBS), squalene-PBS emulsion, Intralipid or liposomes, significantly stimulated the primary and secondary antibody production of guinea-pigs against influenza split or subunit vaccine and inactivated the hepatitis B virus surface (HBs) antigen. Mice seemed less responsive to the adjuvanticity of B30-MDP than guinea-pigs. Two low toxicity lipid A analogues, acylated β(1-6)-d-glucosamine disaccharide bisphosphates (which do not have amide-bound or ester-bound 3-acyloxyacyl groups unlike fully toxic Escherichia coli-type lipid A), caused significantly enhanced antibody responses, primary or secondary, when administered to mice by incorporation into liposomes with inactivated HBs antigen.

Original languageEnglish
Pages (from-to)39-48
Number of pages10
JournalVaccine
Volume7
Issue number1
DOIs
Publication statusPublished - 1989 Feb

Keywords

  • 6-O-acylmuramyldipeptide
  • N-Acetylmuramyl-l-alanyl-d-isoglutamine
  • hepatitis B virus vaccine
  • influenza split vaccine
  • influenza subunit vaccine
  • low toxicity lipid-A analogues
  • muramyldipeptide

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Enhancement of humoral immune responses against viral vaccines by a non-pyrogenic 6-O-acyl-muramyldipeptide and synthetic low toxicity analogues of lipid A'. Together they form a unique fingerprint.

Cite this